New anesthetic patch is launched

June 26, 2006

Zars Pharma has announced the launch of Synera (lidocaine 70 mg/tetracaine 70 mg), a topical patch approved for the prevention of pain associated with superficial venous access and superficial dermatological procedures such as excision, electrodessication, and shave biopsy of skin lesions in patients four months of age and older. Zars Pharma has licensed Synera to Endo Pharmaceuticals for sales and marketing in North America. According

New anesthetic patch is launched

Zars Pharma has announced the launch of Synera (lidocaine 70 mg/tetracaine 70 mg), a topical patch approved for the prevention of pain associated with superficial venous access and superficial dermatological procedures such as excision, electrodessication, and shave biopsy of skin lesions in patients four months of age and older. Zars Pharma has licensed Synera to Endo Pharmaceuticals for sales and marketing in North America. According to a company executive, Synera provides local dermal anesthesia in 20 to 30 minutes and the most common local reactions include erythema, blanching, and edema.

To see more Hot off the Press news articles, click here http://www.drugtopics.com/Hot+off+the+Press.